Long-term pegylated interferon-α and its potential in the treatment of melanoma

References

• IsaacsALindenmannJVirus Interference. I The interferonProc R Soc London Ser B195714725813465720
   PubMed Web of Science ®Google Scholar
• KerrIMStarkGRThe antiviral effects of the interferons and their inhibitionJ Interferon Res1992122372401385551
   PubMedGoogle Scholar
• SamuelCEAntiviral actions of interferonsClin Microbiol Rev20011477880911585785
   PubMed Web of Science ®Google Scholar
• SenGCLengyelPThe interferon system. A bird’s eye view of its biochemistryJ Biol Chem1992267501750201371992
   PubMed Web of Science ®Google Scholar
• NathanCGallinJIGoldsteinIMSchnyderRInterferon and inflammationInflammation: basic principles and clinical correlatesNew YorkRaven Press1992265290
   Google Scholar
• BeattieETartagliaJPaolettiEVaccinia virus-encoded elF-2a homolog abbrogates the anitiviral effect of interferonVirology19911834194221711259
   PubMed Web of Science ®Google Scholar
• BandyopadhyaySPerussiaBTrinchieriGRequirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblastsJ Exp Med19861641801953014033
   PubMed Web of Science ®Google Scholar
• SiegalFPKadowakiNShodellMThe nature of the principal type 1 interferon-producing cells in human bloodScience19992841835183710364556
   PubMed Web of Science ®Google Scholar
• CellaMJarrossayDFacchettiFPlasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferonNat Med1999591992310426316
   PubMed Web of Science ®Google Scholar
• ColonnaMTrinchieriGLiuYJPlasmacytoid dendritic cells in immunityNat Immunol200451219122615549123
   PubMed Web of Science ®Google Scholar
• McKennaKBeignonASBhardwajNPlasmacytoid dendritic cells: linking innate and adaptive immunityJ Virol200579172715596797
   PubMed Web of Science ®Google Scholar
• IwasakiAMedzhitovRToll-like receptor control of the adaptive immune responsesNat Immunol2004598799515454922
   PubMed Web of Science ®Google Scholar
• BellDChomaratPBroylesDIn breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areasJ Exp Med19991901417142610562317
   PubMed Web of Science ®Google Scholar
• VermiWBonecchiRFacchettiFRecruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomasJ Pathol200320025526812754747
   PubMed Web of Science ®Google Scholar
• LiuCLouYLizeeGPlasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in miceJ Clin Invest20081181165117518259609
   PubMed Web of Science ®Google Scholar
• PestkaSLangerJAZoonKCInterferons and their actionsAnnu Rev Biochem1987567277772441659
   PubMed Web of Science ®Google Scholar
• KaplanDHShankaranVDigheASDemonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent miceProc Natl Acad Sci U S A199895755675619636188
   PubMed Web of Science ®Google Scholar
• DunnGPBruceATSheehanKCA critical function for type I interferons in cancer immunoeditingNat Immunol2005672272915951814
   PubMed Web of Science ®Google Scholar
• ParedesJKrownSEInterferon-alpha therapy in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndromeInt J Immunopharmacol199113 Suppl 177811823908
   PubMed Web of Science ®Google Scholar
• BaronSTyringSKFleischmannWRJrThe interferons. Mechanisms of action and clinical applicationsJama1991266137513831715409
   PubMed Web of Science ®Google Scholar
• BordenECHollandJFFreiIIIBastJRKufeDWMortonDLWechselbaumRRInterferonsCancer MedicineMDWiliams and Wilkins199711191212
   Google Scholar
• GuttermanJUCytokine therapeutics: lessons from interferon alphaProc Natl Acad Sci U S A199491119812058108387
   PubMed Web of Science ®Google Scholar
• BuzaidACRobertoneAKisalaCPhase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinomaJ Clin Oncol19875108310893598612
   PubMed Web of Science ®Google Scholar
• KrownSEInterferon treatment of renal cell carcinoma. Current status and future prospectsCancer19875964765110822464
   PubMed Web of Science ®Google Scholar
• Interferon NomenclatureNature19802861106157097
   PubMed Web of Science ®Google Scholar
• PlataniasLCMechanisms of type-I- and type-II-interferon-mediated signallingNat Rev Immunol2005537538615864272
   PubMed Web of Science ®Google Scholar
• PestkaSThe human interferon-alpha species and hybrid proteinsSemin Oncol199724S94
   Web of Science ®Google Scholar
• LaFleurDWNardelliBTsarevaTInterferon-kappa, a novel type I interferon expressed in human keratinocytesJ Biol Chem2001276397653977111514542
   PubMed Web of Science ®Google Scholar
• ConklinDGrantFRixonMInterferon-epsilonUS Patent20026329175
   Google Scholar
• KotenkoSVGallagherGBaurinVVIFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complexNat Immunol20034697712483210
   PubMed Web of Science ®Google Scholar
• PestkaSKrauseCDWalterMRInterferons, interferon-like cytokines, and their receptorsImmunol Rev200420283215546383
   PubMed Web of Science ®Google Scholar
• PestkaSThe human interferon alpha species and receptorsBiopolymers20005525428711169919
   PubMed Web of Science ®Google Scholar
• WeissmannCNagataSBollWStructure and expression of human IFN-alpha genesPhilos Trans R Soc Lond B Biol Sci19822997286128751
   PubMed Web of Science ®Google Scholar
• WeissKSafety profile of interferon-alpha therapySemin Oncol1998259139482535
   PubMed Web of Science ®Google Scholar
• GoodinDSFrohmanEMGarmanyGPJrDisease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesNeurology20025816917811805241
   PubMed Web of Science ®Google Scholar
• Weinstock-GuttmanBJacobsLDWhat is new in the treatment of multiple sclerosis?Drugs20005940141010776827
   PubMed Web of Science ®Google Scholar
• DomanskiPColamoniciORThe type-I interferon receptor. The long and short of itCytokine Growth Factor Rev199671431518899292
   PubMedGoogle Scholar
• SchindlerCShuaiKPreziosoVRInterferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factorScience19922578098131496401
   PubMed Web of Science ®Google Scholar
• FuXYSchindlerCImprotaTThe proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transductionProc Natl Acad Sci U S A199289784078431502204
   PubMed Web of Science ®Google Scholar
• ShuaiKSchindlerCPreziosoVRActivation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding proteinScience1992258180818121281555
   PubMed Web of Science ®Google Scholar
• ChenJBaigEFishNEDiversity and relatedness among the type I interferonsJ Interfon Cytokine Res2004246879698
   PubMed Web of Science ®Google Scholar
• DarnellJEJrKerrIMStarkGRJak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteinsScience1994264141514218197455
   PubMed Web of Science ®Google Scholar
• IhleJNThe Janus protein tyrosine kinase family and its role in cytokine signalingAdv Immunol1995601358607368
   PubMed Web of Science ®Google Scholar
• ParmarSPlataniasLCInterferons: mechanisms of action and clinical applicationsCurr Opin Oncol20031543143914624225
   PubMedGoogle Scholar
• HorvathCMDarnellJEJrThe antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 proteinJ Virol1996706476508523587
   PubMed Web of Science ®Google Scholar
• DarnellJEJrSTATs and gene regulationScience1997277163016359287210
   PubMed Web of Science ®Google Scholar
• AaronsonDSHorvathCMA road map for those who don’t know JAK-STATScience20022961653165512040185
   PubMed Web of Science ®Google Scholar
• MeinkeABarahmand-PourFWohrlSActivation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferonsMol Cell Biol199616693769448943349
   PubMed Web of Science ®Google Scholar
• FarrarJDSmithJDMurphyTLRecruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2J Biol Chem20002752693269710644731
   PubMed Web of Science ®Google Scholar
• TorpeyNMaherSEBothwellALInterferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cellsJ Biol Chem20042792678926789615087447
   PubMed Web of Science ®Google Scholar
• MatikainenSSarenevaTRonniTInterferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cellsBlood19999319801989110068671
   PubMed Web of Science ®Google Scholar
• Fasler-KanEPanskyAWiederkehrMInterferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cellsEur J Biochem19982545145199688261
   PubMedGoogle Scholar
• UddinSMajchrzakBWoodsonJActivation of the p38 mitogen-activated protein kinase by type I interferonsJ Biol Chem1999274301273013110514501
   PubMed Web of Science ®Google Scholar
• GohKCHaqueSJWilliamsBRp38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferonsEMBO J1999185601560810523304
   PubMed Web of Science ®Google Scholar
• LiYSassanoAMajchrzakBRole of p38a Map kinase in type I interferon signalingJ Biol Chem200427997097914578350
   PubMed Web of Science ®Google Scholar
• UddinSYenushLSunXJInterferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinaseJ Biol Chem199527015938159417608146
   PubMed Web of Science ®Google Scholar
• AhmadSAlsayedYMDrukerBJThe type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor proteinJ Biol Chem199727229991299949374471
   PubMed Web of Science ®Google Scholar
• RobertsRMEalyADAlexenkoAPTrophoblast interferonsPlacenta19992025926410329345
   PubMed Web of Science ®Google Scholar
• BazerFWSpencerTEOttTLInterferon tau: a novel pregnancy recognition signalAm J Reprod Immunol1997374124209228295
   PubMed Web of Science ®Google Scholar
• ChenJWoodWInterferon PRO655. Genentech. [US 6,300,475]Patent2003137
   Google Scholar
• EalickSECookWJVijay-KumarSThree-dimensional structure of recombinant human interferon-gammaScience19912526987021902591
   PubMed Web of Science ®Google Scholar
• CarnaudCLeeDDonnarsOCutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cellsJ Immunol19991634647465010528160
   PubMed Web of Science ®Google Scholar
• FruchtDMFukaoTBogdanCIFN-gamma production by antigen-presenting cells: mechanisms emergeTrends Immunol20012255656011574279
   PubMed Web of Science ®Google Scholar
• FlaishonLHershkovizRLantnerFAutocrine secretion of interferon gamma negatively regulates homing of immature B cellsJ Exp Med20001921381138811067886
   PubMed Web of Science ®Google Scholar
• HarrisDPHaynesLSaylesPCReciprocal regulation of polarized cytokine production by effector B and T cellsNat Immunol2000147548211101868
   PubMed Web of Science ®Google Scholar
• PerussiaBKobayashiMRossiMEImmune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factorJ Immunol19871387657743100615
   PubMed Web of Science ®Google Scholar
• SchroderKHertzogPJRavasiTInterferon-gamma: an overview of signals, mechanisms and functionsJ Leukoc Biol20047516318914525967
   PubMed Web of Science ®Google Scholar
• BachEAAguetMSchreiberRDThe IFN gamma receptor: a paradigm for cytokine receptor signalingAnnu Rev Immunol1997155635919143700
   PubMed Web of Science ®Google Scholar
• StarkGRKerrIMWilliamsBRHow cells respond to interferonsAnnu Rev Biochem1998672272649759489
   PubMed Web of Science ®Google Scholar
• BoehmUKlampTGrootMCellular responses to interferon-gammaAnnu Rev Immunol1997157497959143706
   PubMed Web of Science ®Google Scholar
• DummerRCozzioAUrosevicMInterferons in cutaneous T-cell LymphomasHematologica Reports20062137174
   Google Scholar
• Roferon Drug InformationRoche LaboratoriesNutley, NJ
   Google Scholar
• CadaDConvingtonTDrug Facts and ComparisonsSt. Louis MisouriFacts and Comparisons, Inc20001571d1580
   Google Scholar
• CreaseyAAEppsteinDAMarshYVGrowth regulation of melanoma cells by interferon and (2′–5′)oligoadenylate synthetaseMol Cell Biol198337807866865941
   PubMed Web of Science ®Google Scholar
• BuzaidACGrimmEAAli-OsmanFMechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary resultsMelanoma Res199443273307858418
   PubMed Web of Science ®Google Scholar
• AndersonCMBuzaidACSussmanJNitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapyMelanoma Res199881491559610868
   PubMed Web of Science ®Google Scholar
• BernengoMGQuaglinoPCappelloNMacrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patientsMelanoma Res200010556510711641
   PubMed Web of Science ®Google Scholar
• HallerOArnheiterHLindenmannJHost gene influences sensitivity to interferon action selectively for influenza virusNature19802836606627354853
   PubMed Web of Science ®Google Scholar
• SadlerAJWilliamsBRInterferon-inducible antiviral effectorsNat Rev Immunol2008855956818575461
   PubMed Web of Science ®Google Scholar
• AebiMFahJHurtNcDNA structures and regulation of two interferon-induced human Mx proteinsMol Cell Biol19899506250722481229
   PubMed Web of Science ®Google Scholar
• HorisbergerMAMcMasterGKZellerHCloning and sequence analyses of cDNAs for interferon- and virus-induced human Mx proteins reveal that they contain putative guanine nucleotide-binding sites: functional study of the corresponding gene promoterJ Virol199064117111812154602
   PubMed Web of Science ®Google Scholar
• HolzingerDJornsCStertzSInduction of MxA gene expression by influenza A virus requires type I or type III interferon signalingJ Virol2007817776778517494065
   PubMed Web of Science ®Google Scholar
• GilliFMarnettoFCaldanoMBiological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1Mult Scler200612475716459719
   PubMed Web of Science ®Google Scholar
• HallerOKochsGInterferon-induced mx proteins: dynamin-like GTPases with antiviral activityTraffic20023710712230469
   PubMed Web of Science ®Google Scholar
• JakschiesDHochkeppelHKHorisbergerMACorrelation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanomaJ Invest Dermatol199095238S241S1701809
   PubMed Web of Science ®Google Scholar
• RalphSJWinesBDPayneMJResistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. Induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitorsJ Immunol1995154224822567532663
   PubMed Web of Science ®Google Scholar
• YurkovetskyZRKirkwoodJMEdingtonHDMultiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2bClin Cancer Res2007132422242817438101
   PubMed Web of Science ®Google Scholar
• Critchley-ThorneRJYanNNacuSDown-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanomaPLoS Med20074e17617488182
   PubMed Web of Science ®Google Scholar
• TakahashiYKanedaHTakasukaNEnhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cellsCancer Sci2008991650165518754879
   PubMed Web of Science ®Google Scholar
• HanadaTYoshimuraARegulation of cytokine signaling and inflammationCytokine Growth Factor Rev20021341342112220554
   PubMed Web of Science ®Google Scholar
• SakaiITakeuchiKYamauchiHConstitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cellsBlood20021002926293112351404
   PubMed Web of Science ®Google Scholar
• GogasHIoannovichJDafniUPrognostic significance of autoimmunity during treatment of melanoma with interferonN Engl J Med200635470971816481638
   PubMed Web of Science ®Google Scholar
• NordlungJKirkwoodJMiltonBFGVitiligo in patients with metastastic melanoma: a good prognostic signJ Am Acad Dermatol1983689696 Abstract6643767
   PubMed Web of Science ®Google Scholar
• ZeuzemSWelschCHerrmannEPharmacokinetics of peginterferonsSemin Liver Dis200323 Suppl 123812934165
   PubMed Web of Science ®Google Scholar
• WangYSYoungsterSBauschJIdentification of the major positional isomer of pegylated interferon alpha-2bBiochemistry200039106341064010978146
   PubMed Web of Science ®Google Scholar
• PEG-Intron: Drug InformationSchering Corporation
   Google Scholar
• GluePRouzier-PanisRRaffanelCA dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy GroupHepatology20003264765310960463
   PubMed Web of Science ®Google Scholar
• LindsayKLTrepoCHeintgesTA randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis CHepatology20013439540311481625
   PubMed Web of Science ®Google Scholar
• Peg-INFa-2a, Pegasys: Drug Information www.rocheusa.com/products/pegasys/pi.pdf
   Google Scholar
• AlgranantiNSySMobiMA branched methoxy 40 kDa polyethylene glykol (PEG) moiety optimizes the pharmakocinetics (PK) of peginterferon a-2a(PEG-IFN)and may explain its enhanced efficacy in chronic hepatitis C (CHC)Hepatology1999190A Abstract
   Web of Science ®Google Scholar
• BalchCMBuzaidACSoongSJFinal version of the American Joint Committee on Cancer staging system for cutaneous melanomaJ Clin Oncol20011936354811504745
   PubMed Web of Science ®Google Scholar
• DummerRPanizzonRBlochPHUpdated Swiss guidelines for the treatment and follow up of cutaneous melanomaDermatology2005394415604544
   PubMed Web of Science ®Google Scholar
• KirkwoodJMIbrahimJGSondakVKHigh- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J Clin Oncol2000182444245810856105
   PubMed Web of Science ®Google Scholar
• KirkwoodJMManolaJIbrahimJA pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanomaClin Cancer Res200410167016715014018
   PubMed Web of Science ®Google Scholar
• EggermontAMSuciuSMacKieRPost-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialLancet20053661189119616198768
   PubMed Web of Science ®Google Scholar
• KirkwoodJMStrawdermanMHErnstoffMSInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol1996147178558223
   PubMed Web of Science ®Google Scholar
• EggermontAMSuciuSSantinamiMAdjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialLancet200837211712618620949
   PubMed Web of Science ®Google Scholar
• DummerRGarbeCThompsonJARandomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanomaJ Clin Oncol2006241188119416505439
   PubMed Web of Science ®Google Scholar
• MillwaldMJBedikianAYConryRMRandomized multinational phase III trial of dacarbazine(DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advnced maligannt melanoma (MM). Analysis of long-term survivalASCO Annual Meeting Abstract Nr20047505
   Google Scholar
• SchadendorfDUgurelSSchuler-ThurnerBDacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGAnn Oncol20061756357016418308
   PubMed Web of Science ®Google Scholar
• KurokohchiKTakaguchiKKitaKSuccessful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alphaWorld J Gastroenterol2005115401540316149157
   PubMed Web of Science ®Google Scholar
• SonMJSongHSKimMHSynergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastomaInt J Oncol2006281385139216685440
   PubMed Web of Science ®Google Scholar
• KaufmannRSpiethKLeiterUTemozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology GroupJ Clin Oncol2005239001900716260697
   PubMed Web of Science ®Google Scholar
• HwuWJPanageasKSMenellJHPhase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanomaCancer200610624455116639739
   PubMed Web of Science ®Google Scholar
• MiddletonMRGrobJJAaronsonNRandomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaJ Clin Oncol2000181586610623706
   PubMed Web of Science ®Google Scholar
• SpiethKKaufmannRDummerRTemozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)Ann Oncol200819801618178958
   PubMed Web of Science ®Google Scholar
• HauschildADummerRUgurelSCombined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 studyCancer200811314041118615619
   PubMed Web of Science ®Google Scholar
• VaishampayanUNHeilbrunLKMarsackCPhase II trial of pegylated interferon and thalidomide in malignant metastatic melanomaAnticancer Drugs2007181221617893524
   PubMed Web of Science ®Google Scholar
• MedwatchWhat is a serious adverse effect? www.fda.gov retrieved on 2007 09–18
   Google Scholar
• HauschildAGogasHTarhiniAPractical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinionCancer20081129829418236459
   PubMed Web of Science ®Google Scholar
• MalikURMakowerDFWadlerSInterferon-mediated fatigueCancer2001921664811598884
   PubMed Web of Science ®Google Scholar
• Arzneimittel-Kompendium der Schweiz http://www.kompendium.ch/ Copyright by Documed AG Basel, Switzerland 2008
   Google Scholar